[2,5-dichloro-4-(1-methyl-3-indolecarboxamido)phenyl]acetic acid | 441715-25-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: [2,5-dichloro-4-(1-methyl-3-indolecarboxamido)phenyl]acetic acid
• 英文别名: [2,5-dichloro-4-(1-methyl-3-indolylcarbonylamino)phenyl]acetic acid；2,5-dichloro-4-[(1-methyl-1H-indol-3-yl)carboxamido]phenylacetic acid；{2,5-dichloro-4-[(1-methylindol-3-yl)carboxamido]phenyl}acetic acid；(2,5-dichloro-4-((1-methyl-1H-3-indolylcarbonyl)amino)phenyl)acetic acid；2-[2,5-Dichloro-4-[(1-methylindole-3-carbonyl)amino]phenyl]acetic acid
• CAS: 441715-25-9
• 化学式: C₁₈H₁₄Cl₂N₂O₃
• 分子量: 377.227
• InChiKey: MMRAQCCDVVNBQB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  71.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  [2,5-dichloro-4-(1-methyl-3-indolecarboxamido)phenyl]acetic acid 在 4-二甲氨基吡啶 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 18.0h， 生成 trans-4-((2S,4S)-1-{2,5-dichloro-4-[(1-methylindol-3-yl)carboxamido]phenyl}acetyl-4-methoxypyrrolidin-2-yl)methoxycyclohexane-1-carboxylic acid ethyl ester
  参考文献：
  名称：

  EP1623975

  摘要：

  公开号：
• 作为产物：
  描述：

  {2,5-dichloro-4-[(1-methylindol-3-yl)carboxamido]phenyl}acetic acid ethyl ester 在 sodium hydroxide 、 水 、 盐酸 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 4.0h， 生成 [2,5-dichloro-4-(1-methyl-3-indolecarboxamido)phenyl]acetic acid
  参考文献：
  名称：

  EP1623975

  摘要：

  公开号：

文献信息

• VLA-4 INHIBITOR
  申请人：DAIICHI PHARMACEUTICAL CO., LTD.

  公开号：EP1757602A1

  公开（公告）日：2007-02-28

  An object of the present invention is to provide a compound which selectively inhibits binding of a ligand and α4β1 integrin (VLA-4), a process for producing the compound, and a medicament containing the compound. A compound represented by the formula (I) etc. orasaltthereof, a process for producing the compound or a salt thereof, a medicament containing the compound or a salt thereof, as well as a preventive and/or a therapeutic agent for a disease caused by cell adhesion, for example, inflammatory reaction, autoimmune disease, cancer metastasis, bronchial asthma, nasal obstruction, diabetes, arthritis, psoriasis, multiple sclerosis, inflammatory bowel disease and rejection reaction at transplantation, containing the compound or a salt thereof as a primary component. [wherein Y1 represents a divalent aryl group etc. , V1 represents an aryl group etc., and R11 to R14 represent H, OH or a halogen atom etc.]

  本发明的一个目的是提供一种化合物，该化合物选择性地抑制配体与α4β1整合素（VLA-4）的结合，以及包含该化合物的药物的制备过程。化合物的结构如公式（I）所示，或其盐，制备该化合物或其盐的过程，包含该化合物或其盐的药物，以及作为细胞粘附引起的疾病（例如炎症反应、自身免疫疾病、癌症转移、支气管哮喘、鼻阻塞、糖尿病、关节炎、银屑病、多发性硬化症、炎症性肠病和移植排斥反应等）的预防和/或治疗剂，包含该化合物或其盐作为主要成分。【其中Y1代表双价芳基等，V1代表芳基等，R11至R14代表H、OH或卤素原子等】
• Fast Carbon Isotope Exchange of Carboxylic Acids Enabled by Organic Photoredox Catalysis
  作者：Duanyang Kong、Maxime Munch、Qiqige Qiqige、Christopher J. C. Cooze、Benjamin H. Rotstein、Rylan J. Lundgren

  DOI：10.1021/jacs.0c12819

  日期：2021.2.10

  Carbazole/cyanobenzene photocatalysts promote the direct isotopic carboxylate exchange of C(sp3) acids with labeled CO2. Substrates that are not compatible with transition-metal-catalyzed degradation–reconstruction approaches or prone to thermally induced reversible decarboxylation undergo isotopic incorporation at room temperature in short reaction times. The radiolabeling of drug molecules and precursors

  咔唑/氰基苯光催化剂促进带有标记CO 2的C（sp 3）酸的直接同位素羧酸交换。与过渡金属催化的降解-重建方法不兼容或易于发生热诱导的可逆脱羧作用的底物在室温下会在短时间内经历同位素掺入。证明了用[ 11 C] CO 2对药物分子和前体进行放射性标记。
• [EN] VLA-4 INHIBITOR<br/>[FR] INHIBITEUR DE VLA-4
  申请人：DAIICHI SEIYAKU CO

  公开号：WO2005121135A1

  公开（公告）日：2005-12-22

  A compound which selectively inhibits bonding between a ligand and α4β1 integrin (VLA-4); a process for producing the compound; and a medicine containing the compound. The compound is one represented by, e.g., the formula (I) or a salt thereof. Also provided is a preventive and/or therapeutic agent which contains the compound or salt as a major component and is effective against diseases attributable to cell adhesion, such as, e.g., inflammatory reaction, autoimmune disease, cancer metastasis, bronchial asthma, nasal obstruction, diabetes, arthritis, psoriasis, multiple sclerosis, inflammatory intestinal disease, and rejection reaction in transplantation. (In the formula, Y1 represents arylene, etc.; V1 represents aryl, etc.; and R11 to R14 each represents H, OH, halogeno, etc.)

  一种选择性抑制配体与α4β1整合素（VLA-4）结合的化合物；一种生产该化合物的方法；以及含有该化合物的药物。该化合物可由例如式（I）或其盐所代表。还提供了一种预防和/或治疗剂，其含有该化合物或盐作为主要成分，并对由细胞粘附引起的疾病具有有效性，例如炎症反应、自身免疫疾病、癌症转移、支气管哮喘、鼻塞、糖尿病、关节炎、牛皮癣、多发性硬化、炎症性肠道疾病和移植排斥反应等（在该式中，Y1代表芳基等；V1代表芳基等；R11至R14分别代表H、OH、卤素等）。
• A Novel Synthetic Approach to Very Late Antigen-4 Antagonist trans-4-[1-[[2,5-Dichloro-4-(1-methyl-3-indolylcarboxyamide)phenyl]acetyl]-(4S)-methoxy-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic Acid via tert-Butyl trans-[(4S)-Methoxy-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylate as a Key Intermediate
  作者：Jun Chiba、Nobuo Machinaga

  DOI：10.1248/cpb.59.574

  日期：——

  This contribution describes a novel synthetic approach to very late antigen-4 (VLA-4) antagonist trans-4-[1-[[2,5-dichloro-4-(1-methyl-3-indolylcarboxyamide)phenyl]acetyl]-(4S)-methoxy-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic acid (1) via tert-butyl trans-[(4S)-methoxy-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylate (2b) as a key intermediate. The synthesis, which includes n-Bu₄NSO₃H that catalyzed

  这项贡献描述了一种新的合成方法，可用于治疗晚期抗原4（VLA-4）拮抗剂反式4- [1-[[2,5-二氯-4-（1-甲基-3-吲哚基羧酰胺）苯基]乙酰基]- （4S）-甲氧基-（2S）-吡咯烷基甲氧基]环己烷甲酸（1）经叔丁基-[（4S）-甲氧基-（2S）-吡咯烷基甲氧基]环己烷甲酸叔丁酯（2b）为关键中间体。该合成包括利用n-Bu₄NSO₃H催化12的碱性醚化反应和碘介导的环化反应，以提供2b的2,4-二取代的吡咯烷骨架，该合成旨在利用反式-4-羟基环己烷羧酸（9）作为市售原料材料。
• Vla-4 inhibitors
  申请人：——

  公开号：US20040110945A1

  公开（公告）日：2004-06-10

  The present invention relates to a compound represented by the following formula (I): 1 (wherein, W represents W A —A 1 —W B — (in which, W A is substituted or unsubstituted aryl, etc., A 1 is —NR 1 —, single bond, —C(O)—, etc., and W B is substituted or unsubstituted arylene, etc.), R is single bond, —NH—, —OCH 2 —, alkenylene, etc., X is —C(O)—, —CH 2 —, etc., and M is, for example, the following formula: 2 (in which, R 11 , R 12 and R 13 each independently represents hydrogen, hydroxyl, amino, halogen, etc., R 14 is hydrogen or lower alkyl, Y represents —CH 2 —O—, etc., Z is substituted or unsubstituted arylene, etc., A 2 is single bond, etc, and R 10 is hydroxyl or lower alkoxy)), or salt thereof; and a medicament containing the same. This compound or salt thereof selectively inhibits binding of cell adhesion molecules to VAL-4 and exhibits high bioavailability so that it is useful as a preventive and/or remedy for inflammatory diseases, autoimmune diseases, metastasis, bronchial asthma, rhinostenosis, diabetes, and the like.

  本发明涉及以下式(I)所表示的化合物：1（其中，W代表WA-A1-WB-（其中，WA是取代或未取代的芳基等，A1是-NR1-，单键，-C（O）-等，WB是取代或未取代的芳烃基等），R是单键，-NH-，-OCH2-，烯烃基等，X是-C（O）-，-CH2-等，M是例如以下公式：2（其中，R11，R12和R13分别独立地代表氢，羟基，氨基，卤素等，R14是氢或低级烷基，Y代表-CH2-O-等，Z是取代或未取代的芳烃基等，A2是单键等，而R10是羟基或低级烷氧基），或其盐；以及含有该化合物的药物。该化合物或其盐选择性地抑制细胞黏附分子与VAL-4的结合，并表现出高的生物利用度，因此可用作预防和/或治疗炎症性疾病、自身免疫性疾病、转移、支气管哮喘、鼻窦狭窄、糖尿病等。